Spots Global Cancer Trial Database for ponatinib hydrochloride
Every month we try and update this database with for ponatinib hydrochloride cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions | NCT02265341 | Malignant Hepat... | Laboratory Biom... Ponatinib Hydro... Quality-of-Life... | 18 Years - | Mayo Clinic | |
| Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia | NCT02779283 | Acute Lymphobla... Acute Myeloid L... | Cyclophosphamid... Cytarabine Dasatinib Dexamethasone Doxorubicin Hyd... Idarubicin Idelalisib In Vitro Kinase... Leucovorin Calc... Methotrexate Methylprednisol... Ponatinib Hydro... Rituximab Ruxolitinib Pho... Sorafenib Tosyl... Sunitinib Malat... Vincristine Sul... | 18 Years - 64 Years | OHSU Knight Cancer Institute | |
| Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT. | NCT02272998 | Malignant Neopl... | ponatinib hydro... laboratory biom... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia | NCT03576547 | Blast Phase Chr... Philadelphia Ch... Recurrent Acute... Recurrent Chron... Refractory Acut... Refractory Chro... t(9;22) | Dexamethasone Ponatinib Hydro... Rituximab Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults | NCT04530565 | B Acute Lymphob... | Biospecimen Col... Blinatumomab Bone Marrow Asp... Cyclophosphamid... Cytarabine Dasatinib Dexamethasone Doxorubicin Hyd... Echocardiograph... Electrocardiogr... Lumbar Puncture Mesna Methotrexate Multigated Acqu... Ponatinib Hydro... Prednisone Vincristine Sul... | 18 Years - 75 Years | National Cancer Institute (NCI) | |
| Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions | NCT02265341 | Malignant Hepat... | Laboratory Biom... Ponatinib Hydro... Quality-of-Life... | 18 Years - | Mayo Clinic | |
| Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia | NCT03576547 | Blast Phase Chr... Philadelphia Ch... Recurrent Acute... Recurrent Chron... Refractory Acut... Refractory Chro... t(9;22) | Dexamethasone Ponatinib Hydro... Rituximab Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib | NCT01746836 | Chronic Phase C... Philadelphia Ch... Recurrent Chron... | Laboratory Biom... Ponatinib Hydro... Quality-of-Life... | 18 Years - | M.D. Anderson Cancer Center | |
| Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia | NCT01424982 | Accelerated Pha... Acute Lymphobla... Adult Acute Lym... B Acute Lymphob... Blast Phase Chr... Philadelphia Ch... Untreated Adult... | Cyclophosphamid... Cytarabine Dexamethasone Doxorubicin Doxorubicin Hyd... Laboratory Biom... Methotrexate Ponatinib Ponatinib Hydro... Prednisone Rituximab Vincristine Vincristine Sul... | 18 Years - | M.D. Anderson Cancer Center | |
| Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib | NCT01746836 | Chronic Phase C... Philadelphia Ch... Recurrent Chron... | Laboratory Biom... Ponatinib Hydro... Quality-of-Life... | 18 Years - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
